Z. Neeman, D. Sudheendra, J. Coleman, T. Fojo, B.J. Wood; Bethesda/US

Conclusion
Targeting the junction of the tumor and the collecting system with RF ablation may result in an effective and durable response despite not ablating the entire tumor. The goal is not to completely ablate the tumor, but rather to target the tumor collecting system junction or the biopsy tract. Successful clinical outcome with relief of hematuria is possible without being overly aggressive and subjecting the patients to the risks inherent to complete ablation of the tumor. Although it is difficult to draw broad conclusions from a short retrospective series, RF ablation may be an effective therapeutic option for transfusion-dependent cancer-related hematuria and kidney biopsy-related bleeding in patients with multiple comorbidities, renal insufficiency, or solitary kidneys. Those patients who have failed conventional therapies and who are poor surgical candidates may also benefit from this modality.